Phathom Pharmaceuticals, Inc. (PHAT)
NasdaqGS · USD · Healthcare · Biotechnology
$5.94 (+3.48%) as of
Key statistics
- Market cap
- 480.55M
- Forward P/E
- 6.16
- EPS (TTM)
- -1.26
- Dividend yield
- 0.00%
- 52-week range
- 5.01 – 18.31
- Beta
- 0.50
- Revenue (TTM)
- 239.66M
- Profit margin
- -41.34%
- Analyst target
- $19.64
- Volume
- 2.11M
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Florham Park, NJ, United States
- Employees
- 371
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.